UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overexpression of Galectin-7, A Myoepithelial Cell Marker, Enhances Spontaneous Metastasis of Breast Cancer Cells

The American journal of pathology, 2010-06, Vol.176 (6), p.3023-3031

2010

Volltextzugriff (PDF)

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Oncogene, 2018-06, Vol.37 (24), p.3183-3199

2018

Volltextzugriff (PDF)

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas

Clinical cancer research, 2018-12, Vol.24 (24), p.6483-6494

2018

Volltextzugriff (PDF)

Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis

Breast cancer research and treatment, 2013-10, Vol.141 (3), p.331-339

2013

Volltextzugriff (PDF)

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

Clinical cancer research, 2016-12, Vol.22 (24), p.6088-6098

2016

Volltextzugriff (PDF)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

Cell reports (Cambridge), 2022-04, Vol.39 (1), p.110634-110634, Article 110634

2022

Volltextzugriff (PDF)

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

Clinical cancer research, 2010-04, Vol.16 (7), p.2147-2156

2010

Volltextzugriff (PDF)

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

OncoTargets and therapy, 2013-01, Vol.6 (default), p.839-852

2013

Volltextzugriff (PDF)

Osteoactivin Promotes Breast Cancer Metastasis to Bone

Molecular cancer research, 2007-10, Vol.5 (10), p.1001-1014

2007

Volltextzugriff (PDF)

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Heliyon, 2024-05, Vol.10 (9), p.e29668, Article e29668

2024

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report

Kidney medicine, 2022-05, Vol.4 (5), p.100461, Article 100461

2022

Volltextzugriff (PDF)

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Nature reviews. Cancer, 2024-02, Vol.24 (2), p.105-122

2024

Volltextzugriff (PDF)

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer

Pharmacology & therapeutics (Oxford), 2017-11, Vol.179, p.127-141

2017

Volltextzugriff (PDF)

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer

Journal of clinical oncology, 2014-11, Vol.32 (32), p.3619-3625

2014

Volltextzugriff (PDF)

How can we integrate the biology of breast cancer cell dormancy into clinical practice?

Cancer cell, 2024-07, Vol.42 (7), p.1147-1151

2024

Volltextzugriff (PDF)

BRAF Mutation Class and Clinical Outcomes-Letter

Clinical cancer research, 2019-05, Vol.25 (10), p.3188-3188

2019

Volltextzugriff (PDF)

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer

Translational lung cancer research, 2024-04, Vol.13 (4), p.930-935

2024

Volltextzugriff (PDF)

Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'

British journal of cancer, 2018-05, Vol.118 (9), p.1276-1277

2018

Volltextzugriff (PDF)

A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer

Nuclear medicine communications, 2024-08, Vol.45 (8), p.683-689

2024

Volltextzugriff (PDF)

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties

PloS one, 2010-08, Vol.5 (8), p.e12093-e12093

2010

Volltextzugriff (PDF)

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases

Breast cancer research : BCR, 2015-03, Vol.17 (1), p.45-45, Article 45

2015

Volltextzugriff (PDF)

Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program

Clinical and investigative medicine, 2023-03, Vol.46 (1), p.E4-14

2023

Volltextzugriff (PDF)

The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers

Cancers, 2024-01, Vol.16 (2), p.445

2024

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(35)
Oncology
(27)
Humans
(23)
Female
(14)
Animals
(10)
Breast Neoplasms - Pathology
(10)
Metastasis
(10)
Breast Cancer
(9)
Breast Neoplasms - Metabolism
(8)
Cancer
(8)
Cell Line, Tumor
(8)
Melanoma
(8)
Tumors
(8)
Mice
(7)
Proto-Oncogene Proteins B-Raf - Genetics
(7)
Melanoma - Drug Therapy
(6)
Membrane Glycoproteins - Metabolism
(6)
Mutation
(6)
Patients
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overexpression of Galectin-7, A Myoepithelial Cell Marker, Enhances Spontaneous Metastasis of Breast Cancer Cells

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas

Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Osteoactivin Promotes Breast Cancer Metastasis to Bone

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer

How can we integrate the biology of breast cancer cell dormancy into clinical practice?

BRAF Mutation Class and Clinical Outcomes-Letter

The evolving treatment landscape for BRAF-mutated non-small cell lung cancer

Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'

A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases

Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program

HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers

Suchergebnisse filtern